Moderators: TUXI , Blue Skys , Devolution
Search This Board: 
Created: 04/29/2014 07:26:14 PM - Followers: 107 - Board type: Free - Posts Today: 0
News updates July 23rd 2020
"The NeuCovix™ test was compared to a gold standard pseudovirus-based test. NeuCovix™ accurately classified serum from patients who strongly neutralized SARS-CoV-2 and serum from patients who poorly neutralized the virus. Additionally, NeuCovix™ did not cross-react with serum from patients with seasonal respiratory infections including seasonal coronaviruses, suggesting that the test has 100 percent specificity for COVID-19.

July 15, 2020 08:30 ET Source: AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, July 15, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological research, today announced the development of NeuCovixTM, a rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.

Unlike currently available serological COVID-19 tests that detect an antibody response to the virus, AXIM’s rapid 10-minute test measures a specific subpopulation of antibodies to block binding of the virus to host cell receptors. While there are expensive, time consuming laboratory tests that measure neutralizing antibodies, NeuCovixTM differs in that it is a portable, low cost, rapid point-of-care test with results in 10 minutes.

“We are hopeful our test fills an important need in these uncertain times. While other tests merely show whether someone was infected with coronavirus, we took it a step further by creating a test that stratifies individuals into those who have neutralizing antibodies, which are essential in preventing reinfection, and those who don’t. The test can be deployed for point of care use in convalescent plasma transfusions to severely ill patients and for evaluating efficacy of upcoming vaccines in generating protective antibodies,” said Sergei Svarovsky, PhD, MBA, AXIM’s CSO and co-inventor of NeuCovixTM.

An immediate application of NeuCovixTM, a point-of-care test, is to measure levels of neutralizing antibodies in convalescent plasma so that plasma with the highest levels of neutralizing antibodies can be identified and administered to patients fighting COVID-19.  Without this knowledge, many patients could be undertreated with non-neutralizing plasma and may not benefit from this treatment. 

Another application of NeuCovixTM is to help ensure that vaccines elicit high levels of neutralizing antibodies. When a vaccine is available, manufacturers can employ the NeuCovixTM rapid, point-of-care test to evaluate protective immune responses in vaccine recipients.

AXIM® Biotech CEO John W. Huemoeller II commented, Our goal was to make this test, accurate, fast and relatively inexpensive so it could serve as an ‘Immunity Passport port™’ for vaccine developers around the world as they begin larger Phase II and III clinical trials. We are optimistic that NeuCovixTM will be widely used, becoming the gold standard in assessing levels of immunity.

Doug Lake, Ph.D. and co-inventor of NeuCovixTM commented, “Everybody who recovers from COVID-19 makes antibodies against the virus, but since all antibodies are not created equal, you really want to know if the antibodies you make neutralize the virus. People who recover want to make sure they are protected from re-infection and that they won’t infect others.”

AXIM also announced the filing of a pre-Emergency Use Authorization Application (EUA) and has already initiated dialogue with the FDA in order to finalize its EUA submission. The intellectual property relating to the novel serological test is the subject of Provisional Patent Application No. 63/023,646 “Convalescent Plasma Testing and Treatment” filed on May 12, 2020. 

About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated oncology company developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. The Company is also developing novel antibodies for therapeutic and diagnostic uses for oncological therapeutics. For more information, please visit



Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
IgM and IgG are VERY general terms that Devolution 11/11/2021 12:09:23 AM
Are new or just changed your name? 24 06/28/2022 01:01:58 AM
It seems that as soon as that post Squirrel Hunter 06/27/2022 09:22:50 PM
Good question. I was wondering about that Blue Skys 06/27/2022 09:12:17 PM
Why do you think it will go past Squirrel Hunter 06/27/2022 08:55:39 PM
There you go. This is off my screen Tiresias 06/24/2022 06:18:28 PM
Word! 24 06/24/2022 06:03:53 PM
Mepublican mantra. Tiresias 06/24/2022 09:28:35 AM
"You guys may not be following the internet 24 06/23/2022 10:11:00 PM
It's a spec investment and to trade it, Tiresias 06/22/2022 11:24:26 AM
We are already over 1 million shares traded 24 06/22/2022 11:18:26 AM
Those two professions suffer from dry eye-noted-even. Waiting Tiresias 06/22/2022 10:59:38 AM
Right I mean if doctors and bodybuilders are 24 06/21/2022 10:28:17 PM
This can go past .15 soon. jjr04001 06/21/2022 11:44:51 AM
Could be the Doctor and the Bodybuilder. Blue Skys 06/21/2022 10:25:12 AM
A very smart investor buying right out of Blue Skys 06/21/2022 10:00:02 AM
Who defrauded investors? The so called billionaires Tiresias 06/20/2022 08:14:18 PM
My own opinion is that there was a kayakzz 06/20/2022 07:42:44 PM
Another bounce coming. $AXIM jjr04001 06/18/2022 09:07:17 PM
That's interesting. It reads almost like some Blue Skys 06/17/2022 05:17:26 PM
Not to bring up the past but there Dean14 06/17/2022 03:14:21 PM
Hoping this misadventure will be put behind him Tiresias 06/15/2022 05:19:49 PM
And now for something completely different. Tiresias 06/15/2022 05:18:30 PM
He has a sentencing date in a few kayakzz 06/15/2022 11:31:43 AM
New Video TUXI 06/14/2022 08:57:23 PM
No need to worry. John is "Staying Blue Skys 06/14/2022 07:51:31 PM
Did you ever receive a satisfactory response to Tiresias 06/14/2022 07:24:41 PM
You should discuss that with your legal counsel. Tiresias 06/14/2022 01:40:18 PM
Does it mean that AXIM is likely a BesaoT35 06/14/2022 12:29:44 PM
Yes but that should not imply Axiom is Tiresias 06/14/2022 09:06:19 AM
so, John Drago, was Squirrel, the same person janeyH 06/13/2022 05:21:29 PM
...sometimes wolves in sheeps clothing are difficult to identify... gwsteller 06/13/2022 12:53:33 PM
The government writes in response to the United Tiresias 06/13/2022 11:54:36 AM
Sentencing set for 10/21/2022 at 02:00 PM in Tiresias 06/13/2022 11:51:57 AM
AXIM board content is certainly tainted janeyH 06/13/2022 11:46:48 AM
Yes and he was formerly known as The Tiresias 06/13/2022 11:20:03 AM
Squirrel Boy = John Drago????? janeyH 06/13/2022 11:19:05 AM
yes Tiresias 06/13/2022 11:17:12 AM
is this the same Drago: janeyH 06/13/2022 11:11:28 AM
$AXIM Continuing breakout pattern. Increasing technicals SONARSTOCKZ 06/13/2022 10:19:30 AM
double dead squirrel bounce - SCAMOLA janeyH 06/10/2022 04:15:47 PM
Yup. Out for now. Will return jjr04001 06/08/2022 06:49:01 PM
A friend added over a million shares last Blue Skys 06/08/2022 06:02:23 PM
Agree. This Sapphire Biotech team has always TexasMarvL 06/08/2022 01:21:17 PM
My guess is maybe one of the doctors TexasMarvL 06/08/2022 12:52:34 PM
There's your pop in the share price and 24 06/08/2022 12:44:13 PM
Just imagine what the stock price would be Blue Skys 06/08/2022 12:07:24 PM
There is no uncertainty!! The 510K FDA approved DED TexasMarvL 06/08/2022 11:38:41 AM
yup - that was a dead squirrel bounce janeyH 06/08/2022 11:08:38 AM
The market cap is $12 million. If BesaoT35 06/07/2022 11:48:55 AM
I don't care what you call it. jjr04001 06/06/2022 05:40:29 PM
Post Subject